Table 2.
Examples of self-healing hydrogels for cancer drug delivery.
| Self-Healing Mechanisms | Materials | Application | Advantages | Disadvantages | Ref. |
|---|---|---|---|---|---|
| Imine bond | CEC/PEGDA20 hydrogel | Kinetic release drug Dox (2.0 mg Dox/mL hydrogel) |
Suitable gelation time and mechanical strength | - | [35] |
| Thiol bond | CSSH/Cur-Lip | Kinetic release drug Curcomin (200 μM) | Good cytocompatibility | - | [41] |
| Thiol bond | BSA hydrogel | Sustain release drug DOX 100 µg/mL of Dox in 200 µL hydrogel | Biocompatibility, biodegradable, viscoelasticity | Low mechanical strength | [43] |
| Imine bond | Chitosan-PEG | Sustain release TOX(0.37 g TOX) was dissolved in 1800 μL | Biocompatibility, biodegradable | Low mechanical strength | [44] |
| Imine bond | PEI/PDMAEMA/PDA | Sustain release DOX(1 mg/mL) | Biocompatibility, biodegradable, thermosensitive | - | [48] |
| Imine bond | CSMA/BPEI-GO | Loading efficiency 60% (DOX) | Biocompatibility, biodegradable, thermosensitive | - | [49] |
| Ionic interaction | (CAT-Gel)/Fe | DOX (5 mg/kg) and DTX (25 mg/kg) entrapped in CAT-Gel |
Biocompatible, non-hemolytic nature | - | [51] |
| Ionic interaction | MDP | CDN (20 μg/30 μL) | Biocompatible, sustaine release drug | Low mechanical strength | [54] |
| Enzymatic reaction | Fibrin gel | aCD47-Cy5.5 (50 μ per mouse) | Biocompatible, in situ formation therapeutic gel at the tumor resection site, inducing systemic immunological responses | - | [55] |
| Imine bond | mPEG-b-PELG | Co-delivery IL-15 1 μg/mL and CDDP 10 μg/mL in vitro and hydrogel co-loaded with IL-15 (0.5 mg·kg−1) and CDDP (1 mg·kg−1) (Gel + IL-15/CDDP) in vivo |
Biocompatibility, biodegradable, In-situ gelation process at body temperature | - | [56] |